BioLineRx In-Licenses Anti-Inflammatory Peptide

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Exclusive, worldwide rights obtained from two Israeli technology firms covers development and commercialization.

BioLineRx obtained a novel peptide for the treatment of inflammatory diseases from Yissum Research Development Company of the Hebrew University of Jerusalem and Ramot at Tel Aviv University Ltd.

“We believe that BL-4020 offers the potential for a highly effective and safe therapy utilizing a novel mechanism of action,” remarks Morris C. Laster, M.D., CEO of BioLineRx.

BL-4020 is a peptide designed to function as an anti-inflammatory agent in various diseases, such as allergic asthma and colitis. The peptide mimics ManLAM, a protein from the cell surface of Mycobacterium tuberculosis. ManLAM has been shown to modulate the function of the immune system and suppress various inflammatory diseases.

BioLineRx expects that BL-4020, which retains the anti-inflammatory properties of ManLAM, will be effective with low toxicity. In preclinical trials, it was shown to be effective in a wide variety of animal models of inflammation, according to the company.

The worldwide, exclusive license agreement with Yissum and Ramot includes the development and commercialization of BL-4020.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Key takeaways

KPV for rosacea research targets NF-κB signaling. The specific transcription factor driving cathelicidin-mediated inflammation in rosacea lesions, not a broad anti-inflammatory mechanism.
Studies show KPV reduces IL-6 secretion by 68% and IL-8 by 72% in cathelicidin-stimulated dermal cells at 5–10 μM concentration within 24–48 hours.
Topical KPV penetration requires formulation enhancement. Liposomal carriers or DMSO achieve 8-fold higher dermal concentration compared to aqueous solutions.
No FDA-approved rosacea indication exists for KPV as of 2026. Existing evidence comes from in-vitro models, animal dermatitis studies, and small observational cohorts.
Lyophilized KPV must be stored at −20°C before reconstitution and refrigerated at 2–8°C after mixing to maintain peptide stability for the 28-day use window.
Research-grade KPV is available through specialized suppliers like Real Peptides, which synthesize peptides under controlled conditions for investigational applications.

realpeptides.co

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Peptide Therapy Guide Editorial Team

Anti Inflammatory Peptide Amphiphiles | Reading The Applied Value Of Anti Inflammatory Peptide Amphiphiles:Multi-Field Application Summary | Peptide Share

VIP Anti-Inflammatory — Peptide Science | Real Peptides

KPV for Rosacea Research — Anti-Inflammatory Peptide

Inflammation peptides: a complete guide to anti-inflammatory peptide therapy - SeekPeptides